Literature DB >> 19777256

The importance of precise pT diagnosis for prognostic prediction of uterine cervical cancer--a single institutional report at a Japanese comprehensive cancer hospital.

Norihiro Teramoto1, Rieko Nishimura, Koichi Mandai, Takashi Matsumoto, Takamitsu Nogawa, Masamichi Hiura.   

Abstract

We previously reported that the majority of Japanese pathologists misunderstand the International Union against Cancer-pT2 criteria for uterine cervical cancer (UCC). We compared the prognosis of originally diagnosed pT2 (ori-pT) UCC cases at our hospital with reclassified pT2 (re-pT) cases to assess the importance of making a correct pT diagnosis. There were 43 International Federation of Gynecology and Obstetrics (FIGO) II (i.e., cT2) and/or ori-pT2 UCC cases who received surgery without neoadjuvant chemotherapy at Shikoku Cancer Center from 1991 to 2003. The cases (seven ori-pT1 and 36 ori-pT2; 43 cN0 with six pN1) were reclassified as 22 re-pT1 and 21 re-pT2. Fifteen of the 23 ori-pT2a cases (65%) were re-pT1 because their vaginal extension had only been intraepithelial. The difference in the 5-year survival rate (5Y-SR) was not significant between the ori-pT1 and ori-pT2 cases using Fisher's exact test (F test): P = 0.236 > 0.05, whereas 5Y-SR of re-pT1 cases was significantly higher than re-pT2, including pN1 cases and excluding them (F test: P = 0.00164 < 0.01 and P = 0.0108 < 0.05, respectively). The 5Y-SR of ori-pT2-re-pT1 (overdiagnosed pT2) was significantly higher that of ori-pT2-re-pT2 (true pT2) including pN1 cases and excluding them (F test: P = 0.00694 < 0.01 and P = 0.0305 < 0.05, respectively). These results indicated that pT2 of UCC could be frequently misdiagnosed at an institutional level, and that misdiagnosed pT2 might impair the evidence-based medicine of UCC. Multi-institutional assessment of the accuracy of pTNM is recommended, because it is not likely that this is an endemic problem to our hospital.

Entities:  

Mesh:

Year:  2009        PMID: 19777256     DOI: 10.1007/s00428-009-0836-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-01       Impact factor: 3.561

2.  Accuracy of recorded tumor, node, and metastasis stage in a comprehensive cancer center.

Authors:  James D Brierley; Pamela A Catton; Brian O'Sullivan; Janet E Dancey; Anthony J Dowling; Jonathan C Irish; Thomas S McGowan; Jeremy F G Sturgeon; Carol J Swallow; George B Rodrigues; Tony Panzarella
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

3.  Pathology quality control in the cooperative clinical cancer trial programs.

Authors:  R L Kempson
Journal:  Cancer Treat Rep       Date:  1985-10

4.  Re-classification of pTNM staging for lung cancer: single-institution report at a Japanese comprehensive cancer hospital.

Authors:  Norihiro Teramoto; Rieko Nishimura; Hiroyuki Takahata; Shigeki Sawada; Tetsu Shinkai; Koichi Mandai
Journal:  Pathol Int       Date:  2009-06       Impact factor: 2.534

5.  Present situation of pTNM classification in Japan: questionnaire survey of the pathologists of Gan-shinryo-renkei-kyoten Byoin (local core cancer hospitals) on pTNM classification.

Authors:  Norihiro Teramoto; Masahito Tanimizu; Rieko Nishimura
Journal:  Pathol Int       Date:  2009-03       Impact factor: 2.534

6.  Statistical and empirical evaluation of histopathologic reviews for quality assurance in the Eastern Cooperative Oncology Group.

Authors:  K W Gilchrist; D P Harrington; B C Wolf; R S Neiman
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

  6 in total
  1 in total

1.  Evaluation of a Web-Based App Demonstrating an Exclusionary Algorithmic Approach to TNM Cancer Staging.

Authors:  Matthew Kim
Journal:  JMIR Cancer       Date:  2015-04-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.